Ascendis Pharma to Present Key Data on Rare Endocrine Disease Treatments at ENDO 2026
Event summary
- Ascendis Pharma will present data on hypoparathyroidism, achondroplasia, and pediatric growth hormone deficiency at ENDO 2026.
- Two oral presentations and three posters will showcase long-term safety and efficacy of TransCon PTH and TransCon CNP.
- Key trials include the Phase 3 PaTHway trial for hypoparathyroidism and the Phase 2 COACH trial for achondroplasia.
- ENDO 2026 takes place in Chicago from June 13-16, 2026.
The big picture
Ascendis Pharma's presentations at ENDO 2026 highlight its focus on rare endocrine diseases, an area with significant unmet medical needs. The company's TransCon technology platform aims to deliver best-in-class therapies, potentially capturing market share in hypoparathyroidism, achondroplasia, and pediatric growth hormone deficiency. The strategic emphasis on long-term safety and efficacy data underscores Ascendis' commitment to differentiating its pipeline in a competitive biopharmaceutical landscape.
What we're watching
- Clinical Validation
- Whether the long-term data from TransCon PTH and TransCon CNP trials will reinforce their transformative potential in rare endocrine diseases.
- Regulatory Pathway
- The pace at which Ascendis can advance these therapies toward regulatory approval based on the presented data.
- Market Differentiation
- How Ascendis positions these treatments against existing and emerging therapies for hypoparathyroidism and achondroplasia.